The Assembly Hall of the Maternal and Child Hospital of Málaga has hosted the presentation of the Genomic Medicine Program of the ‘Precision Medicine Infrastructure linked to Science and Technology’ (IMPaCT-GENÓMICA) project, in which the Regional Hospital of Málaga participates together with Biomedical. Research Institute of Malaga and the Nanomedicine Platform (IBIMA BIONAND Platform).
The said presentation was led by Raquel Yahyaoui, Medical Specialist in Clinical Biochemistry of the Hospital Regional Universitario de Málaga and Deputy Coordinator of IBIMA-Rare Area, who presented the necessary selection criteria for all professionals to participate in the study, how it is clinical from patients aspects relating to the process of information gathering and, inter alia, the diagnostic process.
The main objective of this program is to provide the National Health System (SNS) with a framework that is the basis for the implementation of genomic medicine in the SNS. In this way, patients affected by rare diseases can access objectivity and adequate response times, thanks to this initiative, with highly complex genomic tests.
In this sense, Yahyaoui said that “participating in this type of project is very important because it allows us to provide patients with rare diseases in the province the opportunity to receive a genetic diagnosis, when at the level of care we previously had Used equipment.” tired. In addition, this program will allow to obtain a lot of information about the human genome. These data used in research will improve knowledge of rare diseases, favoring more accurate diagnosis and more personalized treatment”; Something that, the deputy coordinator of IBIMA-Rare Sector has acknowledged that “this program is aligned with the translational nature of the biomedical research being carried out at the institute”.
Personalized Medicine and the IMPaCT Project
Personalized precision medicine represents the evolution of the practice of medicine through all scientific knowledge generated through biomedicine, which becomes the engine of innovation and technological development. This approach, currently being applied with good results in various health sectors, is also being developed in the field of rare diseases, which together with early and accurate diagnosis form a basic pillar in the approach to this type of disease. .
IMPaCT is a science and technology linked Precision Medicine infrastructure configured around three strategic axes (IMPaCT-GENOMICS, IMPaACT-Data and IMPaCT-Cohort). These programmes, individually or within IMPaCT as a whole, provide a service to the R&D&I system oriented towards precision medicine to promote sci-tech excellence, equity and generation and transfer of knowledge of the highest quality in SNS are designed to provide. Efficiency in the use of available resources. The three programs serve as an initial pivot of action that should structure the coherent incorporation of complementary areas of the future.
The Genomic Medicine Program is coordinated by Dr. Angel Carracedo and will provide genomic support to the Precision Medicine Program, which will provide services intended to help diagnose people who cannot be diagnosed by routine care methods . To meet the objectives of IMPaCT-GENÓMICA, the program is divided into 5 work packages: coordination, network of genomic analysis centers supporting SNS, in rare diseases, in cancer, and clinical in pharmacogenomics and population genomics. Translation in practice. The network is made up of national sector professionals from all areas of genomic medicine support.
This program is supported and funded by the Center for Networked Biomedical Research on Rare Diseases (CIBERER), the Carlos III Health Institute (ISCIII) and the European Regional Development Fund (FEDER).